Piramal Pharma Delivers Strong Q2FY27 Results and Upgrades Full-Year Guidance
Piramal Pharma Ltd · Investor Presentation · 28 Oct 2026, 2:36 am
Piramal Pharma Delivers Strong Q2FY27 Results and Upgrades Full-Year Guidance Piramal Pharma reported consolidated Q2FY27 revenue of ₹2,617 Cr, up 28% YoY, led by CDMO (+36%) and CHG (+32%). EBITDA surged 72% YoY to ₹385 Cr, with margins expanding 372 bps YoY to 14.7% due to operational leverage and cost optimization. PAT turned positive to ₹5 Cr versus a ₹99 Cr loss in Q2FY26. H1FY27 revenue rose 23% YoY to ₹4,887 Cr. Management raised its FY27 revenue growth guidance to 19–20%, expecting meaningfully higher profitability as H2 is typically stronger.
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund · 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 · 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. · 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. · 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 · 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
- Please find enclosed unaudited financial results for Q2 FY 27 · 28 Oct 2026
- Outcome of Board Meeting of Piramal Pharma Limited held on 27th October, 2026 · 28 Oct 2026
